NEW YORK, NY -- (Marketwire) -- 12/27/12 -- TNI BioTech, Inc. (PINKSHEETS: TNIB), a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using patented immunotherapy, is pleased to announce that Umbrella Research has initiated coverage on TNI Biotech, Inc. The full report is posted on the Company web site at http://www.tnibiotech.com/investor-relations/reports or it can be accessed by clicking on the link http://umbresearch.com/Research_Reports.html
About TNI BioTech, Inc.
TNI BioTech, Inc., is a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.
Our proprietary technology, therapies and patents, will be used to treat a wide range of cancers. Our most advanced clinical programs involve immunotherapy that works by isolating a patient's lymphocytes and then incubating them together with Methionine Enkephalin (MENK) in an enriching external incubation system. After incubation the patient's lymphocytes are re-infused back into the patient where they combat and destroy tumor cells.
Even though Management considers any condition that results in altered-immune response a target for investigation, the Company will most likely pursue additional investigations for MENK as a valuable candidate in the treatment of the following:
About Umbrella Research
Umbrella Research LLC was created to fill a growing information vacuum in the equity universe as diminishing investment banking prospects have resulted in the underinvestment of traditional sell side research support for small cap and emerging growth companies. Umbrella Research is a research and advisory platform focused on lesser known companies where its research, whitepapers and investor outreach can create greater incremental value to both the subject companies and investors. All of Umbrella's publishing analysts have significant sector focused experience in traditional sell side models. Its in-depth, fundamental research is designed to educate and inform investors with an emphasis on factual data and tangible performance metrics. The research is available to investors through Umbrella's proprietary distribution list as well as on the company's website at www.UMBresearch.com. Umbrella's advisory services include analysis of potential growth funding mechanisms, creation of marketing materials and presentations, investor pitch, preparation for Q&A, introduction to placement agents and funding sources, assistance drafting legal docs required for financing...etc.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release includes various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company's expectations or beliefs concerning future events. Statements containing expressions such as "believes," "anticipates," "intends," or "expects," used in the Company's press releases and in Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve risks and uncertainties. Although the Company believes its expectations are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there can be no assurances that actual results will not differ materially from expected results. The Company cautions that these and similar statements included in this report are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.